{"id":46307,"date":"2025-11-11T12:31:35","date_gmt":"2025-11-11T04:31:35","guid":{"rendered":"https:\/\/flcube.com\/?p=46307"},"modified":"2025-11-11T12:31:36","modified_gmt":"2025-11-11T04:31:36","slug":"mabwells-9mw3811-gains-nmpa-approval-to-launch-world%e2%80%91first-il%e2%80%9111%e2%80%91targeting-phase-2-trial-for-pathological-scarring","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=46307","title":{"rendered":"Mabwell\u2019s 9MW3811 Gains NMPA Approval to Launch World\u2011First IL\u201111\u2011Targeting Phase\u202f2 Trial for Pathological Scarring"},"content":{"rendered":"\n<p><strong>Mabwell Bioscience (<a href=\"https:\/\/www.google.com\/finance\/quote\/688062:SHA\">SHA: 688062<\/a>)<\/strong> announced that its proprietary monoclonal antibody <strong>9MW3811<\/strong> has received clearance from the <strong>China National Medical Products Administration (NMPA)<\/strong> to commence a <strong>Phase\u202f2 clinical study<\/strong> focused on <strong>pathological scarring<\/strong>. 9MW3811 is the <strong>first IL\u201111\u2011targeting therapeutic<\/strong> to reach clinical development for this indication.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-amp-development-milestones\">Deal &amp; Development Milestones<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Milestone<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Regulatory Milestone<\/strong><\/td><td>NMPA approval to start Phase\u202f2 trial (pathological scarring)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Pathological scarring (keloid, hypertrophic scar)<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>Category\u202f1 therapeutic biologic \u2013 humanized anti\u2011IL\u201111 IgG<\/td><\/tr><tr><td><strong>Previous Indications<\/strong><\/td><td>Advanced malignant tumors, idiopathic pulmonary fibrosis (Phase\u202f1 completed)<\/td><\/tr><tr><td><strong>Phase\u202f1 Results<\/strong><\/td><td>Good safety, half\u2011life &gt;\u202f30\u202fdays in Australia &amp; China<\/td><\/tr><tr><td><strong>Planned Start<\/strong><\/td><td>Late\u202f2025 (China)<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Mabwell (688062.SH)<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>11\u202fNov\u202f2025<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-scientific-rationale\">Scientific Rationale<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target:<\/strong> Interleukin\u201111 (IL\u201111) \/ IL\u201111R\u03b1 signaling, a key driver of fibroblast activation and extracellular\u2011matrix deposition in fibrotic diseases.<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> 9MW3811 binds IL\u201111 with picomolar affinity, blocking downstream STAT3\u2011mediated transcription that fuels scar formation.<\/li>\n\n\n\n<li><strong>Pre\u2011clinical Evidence:<\/strong><\/li>\n\n\n\n<li><strong>Pulmonary fibrosis models:<\/strong> Significant reduction in collagen deposition and lung stiffness.<\/li>\n\n\n\n<li><strong>Human\u2011derived keloid xenograft models:<\/strong> \u2193 scar volume\u202f>\u202f45\u202f% and marked histologic reversal of fibrosis.<\/li>\n\n\n\n<li><strong>Uterine bleeding models:<\/strong> Attenuated endometrial fibrosis, suggesting broader gynecologic utility.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-amp-competitive-landscape\">Market &amp; Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Unmet Need:<\/strong> Pathological scarring affects <strong>\u2248\u202f30\u202fmillion<\/strong> patients worldwide, with limited therapeutic options beyond surgery and corticosteroids.<\/li>\n\n\n\n<li><strong>Potential Revenue:<\/strong> Global scar\u2011treatment market projected to exceed <strong>$5\u202fbillion<\/strong> by 2030; a disease\u2011modifying biologic could capture a <strong>double\u2011digit<\/strong> share.<\/li>\n\n\n\n<li><strong>Competitive Edge:<\/strong> 9MW3811 is the <strong>only IL\u201111\u2011targeted agent<\/strong> in clinical development, positioning Mabwell as a first\u2011mover in a novel fibrosis pathway.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-amp-investor-implications\">Financial &amp; Investor Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>R&amp;D Funding:<\/strong> Mabwell earmarks <strong>RMB\u202f300\u202fmillion<\/strong> (\u2248\u202fUS$42\u202fmillion) for the Phase\u202f2 program, funded largely from existing cash reserves and a recent <strong>private placement<\/strong>.<\/li>\n\n\n\n<li><strong>Share Reaction:<\/strong> Shanghai\u2011listed shares rose <strong>\u2248\u202f4.1\u202f%<\/strong> in early trading, reflecting investor confidence in the differentiated mechanism.<\/li>\n\n\n\n<li><strong>Future Outlook:<\/strong> Successful Phase\u202f2 read\u2011out could unlock <strong>global Phase\u202f3 partnerships<\/strong> and accelerate <strong>licensing discussions<\/strong> with multinational pharma seeking anti\u2011fibrotic pipelines.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the development timeline, regulatory expectations, and commercial potential of 9MW3811. Actual results may differ due to risks including clinical trial outcomes, regulatory approvals, and market acceptance.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Mabwell Bioscience (SHA: 688062) announced that its proprietary monoclonal antibody 9MW3811 has received clearance from&#8230;<\/p>\n","protected":false},"author":1,"featured_media":46310,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,118,1129],"class_list":["post-46307","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-mabwell-bioscience","tag-sha-688062"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Mabwell\u2019s 9MW3811 Gains NMPA Approval to Launch World\u2011First IL\u201111\u2011Targeting Phase\u202f2 Trial for Pathological Scarring - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Mabwell Bioscience (SHA: 688062) announced that its proprietary monoclonal antibody 9MW3811 has received clearance from the China National Medical Products Administration (NMPA) to commence a Phase\u202f2 clinical study focused on pathological scarring. 9MW3811 is the first IL\u201111\u2011targeting therapeutic to reach clinical development for this indication.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=46307\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mabwell\u2019s 9MW3811 Gains NMPA Approval to Launch World\u2011First IL\u201111\u2011Targeting Phase\u202f2 Trial for Pathological Scarring\" \/>\n<meta property=\"og:description\" content=\"Mabwell Bioscience (SHA: 688062) announced that its proprietary monoclonal antibody 9MW3811 has received clearance from the China National Medical Products Administration (NMPA) to commence a Phase\u202f2 clinical study focused on pathological scarring. 9MW3811 is the first IL\u201111\u2011targeting therapeutic to reach clinical development for this indication.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=46307\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-11T04:31:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-11T04:31:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1105.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46307#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46307\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Mabwell\u2019s 9MW3811 Gains NMPA Approval to Launch World\u2011First IL\u201111\u2011Targeting Phase\u202f2 Trial for Pathological Scarring\",\"datePublished\":\"2025-11-11T04:31:35+00:00\",\"dateModified\":\"2025-11-11T04:31:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46307\"},\"wordCount\":370,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46307#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1105.webp\",\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Mabwell Bioscience\",\"SHA: 688062\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=46307#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46307\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=46307\",\"name\":\"Mabwell\u2019s 9MW3811 Gains NMPA Approval to Launch World\u2011First IL\u201111\u2011Targeting Phase\u202f2 Trial for Pathological Scarring - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46307#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46307#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1105.webp\",\"datePublished\":\"2025-11-11T04:31:35+00:00\",\"dateModified\":\"2025-11-11T04:31:36+00:00\",\"description\":\"Mabwell Bioscience (SHA: 688062) announced that its proprietary monoclonal antibody 9MW3811 has received clearance from the China National Medical Products Administration (NMPA) to commence a Phase\u202f2 clinical study focused on pathological scarring. 9MW3811 is the first IL\u201111\u2011targeting therapeutic to reach clinical development for this indication.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46307#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=46307\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46307#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1105.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1105.webp\",\"width\":1080,\"height\":608,\"caption\":\"Mabwell\u2019s 9MW3811 Gains NMPA Approval to Launch World\u2011First IL\u201111\u2011Targeting Phase\u202f2 Trial for Pathological Scarring\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46307#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mabwell\u2019s 9MW3811 Gains NMPA Approval to Launch World\u2011First IL\u201111\u2011Targeting Phase\u202f2 Trial for Pathological Scarring\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Mabwell\u2019s 9MW3811 Gains NMPA Approval to Launch World\u2011First IL\u201111\u2011Targeting Phase\u202f2 Trial for Pathological Scarring - Insight, China&#039;s Pharmaceutical Industry","description":"Mabwell Bioscience (SHA: 688062) announced that its proprietary monoclonal antibody 9MW3811 has received clearance from the China National Medical Products Administration (NMPA) to commence a Phase\u202f2 clinical study focused on pathological scarring. 9MW3811 is the first IL\u201111\u2011targeting therapeutic to reach clinical development for this indication.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=46307","og_locale":"en_US","og_type":"article","og_title":"Mabwell\u2019s 9MW3811 Gains NMPA Approval to Launch World\u2011First IL\u201111\u2011Targeting Phase\u202f2 Trial for Pathological Scarring","og_description":"Mabwell Bioscience (SHA: 688062) announced that its proprietary monoclonal antibody 9MW3811 has received clearance from the China National Medical Products Administration (NMPA) to commence a Phase\u202f2 clinical study focused on pathological scarring. 9MW3811 is the first IL\u201111\u2011targeting therapeutic to reach clinical development for this indication.","og_url":"https:\/\/flcube.com\/?p=46307","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-11T04:31:35+00:00","article_modified_time":"2025-11-11T04:31:36+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1105.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=46307#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=46307"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Mabwell\u2019s 9MW3811 Gains NMPA Approval to Launch World\u2011First IL\u201111\u2011Targeting Phase\u202f2 Trial for Pathological Scarring","datePublished":"2025-11-11T04:31:35+00:00","dateModified":"2025-11-11T04:31:36+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=46307"},"wordCount":370,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=46307#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1105.webp","keywords":["Clinical trial approval \/ initiation","Mabwell Bioscience","SHA: 688062"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=46307#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=46307","url":"https:\/\/flcube.com\/?p=46307","name":"Mabwell\u2019s 9MW3811 Gains NMPA Approval to Launch World\u2011First IL\u201111\u2011Targeting Phase\u202f2 Trial for Pathological Scarring - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=46307#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=46307#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1105.webp","datePublished":"2025-11-11T04:31:35+00:00","dateModified":"2025-11-11T04:31:36+00:00","description":"Mabwell Bioscience (SHA: 688062) announced that its proprietary monoclonal antibody 9MW3811 has received clearance from the China National Medical Products Administration (NMPA) to commence a Phase\u202f2 clinical study focused on pathological scarring. 9MW3811 is the first IL\u201111\u2011targeting therapeutic to reach clinical development for this indication.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=46307#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=46307"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=46307#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1105.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1105.webp","width":1080,"height":608,"caption":"Mabwell\u2019s 9MW3811 Gains NMPA Approval to Launch World\u2011First IL\u201111\u2011Targeting Phase\u202f2 Trial for Pathological Scarring"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=46307#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Mabwell\u2019s 9MW3811 Gains NMPA Approval to Launch World\u2011First IL\u201111\u2011Targeting Phase\u202f2 Trial for Pathological Scarring"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1105.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/46307","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=46307"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/46307\/revisions"}],"predecessor-version":[{"id":46311,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/46307\/revisions\/46311"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/46310"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=46307"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=46307"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=46307"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}